The ICTS has supported a variety of funding programs during our history to meet the timely needs of our membership.

ICTS former funding programs that are currently inactive:

Child Health Challenge (Ch2)

Note: This funding mechanism is not accepting applications at this time.

The Research Forum – Child Health, a joint initiative of the Children’s Discovery Institute and the Institute of Clinical and Translational Sciences, is sponsoring a novel funding program called the Child Health Challenge (CH2)*. The goal of the CH2 program is to move child health-related research projects along the translational spectrum from preclinical (T0/T1) studies to placing pragmatic solutions into patient practice (T3/T4). Funding (up to $25,000 direct costs; 12 month award) is available to support investigators needing to obtain essential preliminary, proof-of-concept or final data leading to a significant publication or an extramural grant application.

*The CH2 Funding Program was modeled after the Pitt Innovation Challenge at the University of Pittsburgh CTSI.

Child Health Challenge (CH2) Competition

Contact Information

If you have questions, send an email to icts@wustl.edu or call Dr. Betsy Keath at  314-747-8155.

Awards

View a listing of all CH2 awards to date (pdf).

Opioid Epidemic Research Funding Program

Note: This funding mechanism is not accepting applications at this time.

The Washington University Institute of Clinical and Translational Sciences (ICTS) and Institute for Public Health announce a new pilot funding program focused on strategies to address the opioid epidemic. Three or more grants of up to $50,000 each will be awarded with a start date of March 1, 2018.

Proposals should describe a clear link to future funding opportunities, such as specific NIH program announcements or other federal or private funding opportunities. Applications should address one or more of the broad themes described in the July 17 report on a National Strategy to Reduce the Opioid Epidemic published by the National Academies of Sciences, Engineering, and Medicine.

Proposals addressing early and late state translational research will be considered for this new pilot program. Examples of appropriate early stage translational research questions include research to:

  • improve understanding of the neurobiology of pain
  • promote discovery and evaluation of innovative treatment modalities, including non-addictive analgesics and non-pharmacologic approach
  • improve understanding of the intersection between pain and opiate use disorder

Later stage translational research that tests the efficacy or effectiveness of strategies to address the opioid epidemic are also sought, including strategies to restrict supply of opiates, influence prescribing practices, reduce demand, and reduce harm. Examples of appropriate later stage translational studies include research to:

  • promote more judicious prescribing of opioids
  • expand access to inpatient and outpatient treatment for opioid use disorder, including in hospitals
  • prevent overdose deaths
  • measure societal impacts in opioid-related regulatory decisions
  • test innovative models of chronic pain management

Awards

2018 Cohort (pdf)

Contact Information

Send us an email at icts@wustl.edu if you have questions or call Jaimee Stagner at 314-362-6325.

Call for Proposals

Patient Safety & Quality Improvement Research Grant Program (PSQI)

Note: This funding mechanism is not accepting applications at this time.

The Washington University School of Medicine (WUSM) Faculty Practice Plan (FPP) announced the Patient Safety & Quality Improvement Research Grant Program in 2014. The ICTS Administrative Core executed the management of the program.

This funding mechanism is not accepting applications at this time. For patient safety and quality improvement projects in FY16, consider the following funding mechanisms.

Awards

Six awards were funded starting 4/1/2015.

2015 Cohort (pdf)

Strategic Pharma-Academic Research Consortium Funding Program (SPARC)

Note: This funding mechanism is not accepting applications at this time.

The Washington University (WU) Institute of Clinical and Translational Sciences (ICTS) and Indiana University (IU) Clinical and Translational Science Center (CTSI) announce the Strategic Pharma-Academic Research Consortium (SPARC) Funding Program for clinical and translational research.

Applications to this program are limited to a total of $400,000 with a 2-year maximum duration for all collaborating institutions.

Consortium Members Include

Industry:

  • Eli Lilly and Company
  • Takeda Pharmaceuticals International, Inc. 

Academic Institutions:

  • Indiana Clinical Translational Science Institute (ICTSI)
  • Ohio State University Center for Translational Sciences (CCTS)
  • Northwestern University Clinical and Translational Science (NUCATS)
  • Washington University in St. Louis Institute of Clinical and Translational Research (WU ICTS)
  • University of Chicago Institute for Translational Medicine (UC-ITM)

Eligibility

All full-time faculty, regardless of tenure status, having a primary appointment within the institutions of the consortium members as Assistant Professor or Assistant Scientist and above.

Objectives

The SPARC Funding Program provides ICTS members with the opportunity to apply for funds to advance medical knowledge relating to autoimmune diseases and the understanding of autoimmune disease. This program intends to foster interactions between Academic and Industry Members enabling them to participate in and conduct pharmaceutical related research projects in the non-competitive intellectual property space, including but not limited to, early translational medicine and potential identification of therapeutic targets in the area of human Autoimmune Diseases.

To be considered, the proposed project must demonstrate the following:

  • Have at least two (2) Project Specific Personnel from different Academic Member institutions (see consortium list above) for which such institutions agree to contribute the requisite cost share funding for the research proposal.
  • Address the non-competitive space of mutual interest to the Members and scientific and technological research challenges confronting translational research.
  • Include the Research Plan and related budget for the study proposal.
  • Agrees to the maximum indirect cost rate for 20%.

Mechanisms

The WU ICTS and the IU CTSI expect to issue an annual call for proposals with award types determined each year based on the SPARC program priorities.

WU-specific Information

Any WU investigator invited to submit a full application must receive Institutional approval for the reduced overhead rate, prior to submission.

Contact Information

For questions regarding:

Scope, contact Anne Nguyen at ictsi@iu.edu.

Financial issues related to budgeting and grant submissions, contact Indiana CTSI Office at ictsi@iu.edu or 317-278-2874.

WU contact: Christina Gurnett – gurnettc@wustl.edu

Awards

View a listing of all SPARC awards (pdf) to date.

Call for Proposals

Deadlines for the last call were:
Letter of Intent Deadline: Friday, March 18, 2016
Full Application Deadline, for selected applicants only: Friday, June 17, 2016
Announcements/Recommendations: August 2016
Project Start Date: September 1, 2016

Application Material
Program Overview and Instructions for WU (pdf)
Application forms can be obtained from the ICTSI site (see Instructions, page 6)

NIH Funding Acknowledgment

  • UL1 TR002345
  • KL2 TR002346
  • TL1 TR002344

Acknowledgement Statement (pdf)

PMCID Instructions (pdf)

Contact icts@wustl.edu or 314-362-9829 for assistance.